ADC Therapeutics SA
COMBINATION THERAPY

Last updated:

Abstract:

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD19 Antibody Drug Conjugate (anti-CD19 ADC) and an anti-BCL-2 agent.

Status:
Application
Type:

Utility

Filling date:

30 Aug 2019

Issue date:

21 Oct 2021